Role of the viral hemagglutinin in the anti-influenza virus activity of newly synthesized polycyclic amine compounds

Antiviral Research

Volumn 99, Issue 3, 2013, Pages 281-291

  Torres, Eva ^a   Duque, María D ^a   Vanderlinden, Evelien ^b   Ma, Chunlong ^c   Pinto, Lawrence H ^c   Camps, Pelayo ^a   Froeyen, Mathy ^b   Vázquez, Santiago ^a   Naesens, Lieve ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Amantadine; Hemagglutinin; Influenza A virus; M2 protein; Polycyclic amines

Indexed keywords

AMANTADINE; AMINE; POLYCYCLIC AMINE DERIVATIVE; POLYCYCLIC HYDROCARBON; PROTON; PYRROLIDINE DERIVATIVE; RIMANTADINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; ANTIVIRUS AGENT; HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ; N METHYL DEXTRO ASPARTIC ACID; PROTEIN M2; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ADAMANTANE DERIVATIVE; AMIDINE; DODECANE; GUANIDINE DERIVATIVE; MEMANTINE; NITROGEN; RIBAVIRIN; RIMANTADINE; ZANAMIVIR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HEMOLYSIS; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A M2; NONHUMAN; PH; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; WILD TYPE; 3-(4,5-DIMETHYLTHIAZOL-2-YL)-5-(3-CARBOXYMETHOXYPHENYL)-2-(4-SULFOPHENYL)-2H-TETRAZOLIUM; AMT; CHEMICAL STRUCTURE; CHEMISTRY; CPE; CYTOPATHOGENIC EFFECT; DRUG EFFECT; GENETICS; HA; HIGH RESOLUTION MASS SPECTRA; HRMS; HUMAN; INFLUENZA; MADIN-DARBY CANINE KIDNEY; MDCK; METABOLISM; MTS; N-METHYL-D-ASPARTATE; POLYCYCLIC AMINES; SYNTHESIS; TEV; TM; TRANSMEMBRANE; TWO-ELECTRODE VOLTAGE CLAMPS; VIROLOGY; WILD-TYPE; WT; DRUG EFFECTS; INFLUENZA, HUMAN; ANIMAL CELL CULTURE; CYTOTOXICITY; INFLUENZA VIRUS; MDCK CELL; THIN LAYER CHROMATOGRAPHY; VIRUS STRAIN; VOLTAGE CLAMP;

3-(4,5-DIMETHYLTHIAZOL-2-YL)-5-(3-CARBOXYMETHOXYPHENYL)-2-(4-SULFOPHENYL)-2H-TETRAZOLIUM; AMANTADINE; AMT; CPE; CYTOPATHIC EFFECT; HA; HEMAGGLUTININ; HIGH RESOLUTION MASS SPECTRA; HRMS; INFLUENZA A VIRUS; M2 PROTEIN; MADIN-DARBY CANINE KIDNEY; MDCK; MTS; N-METHYL-D-ASPARTATE; NMDA; POLYCYCLIC AMINES; TEV; TM; TRANSMEMBRANE; TWO-ELECTRODE VOLTAGE CLAMPS; WILD-TYPE; WT;

AMANTADINE; AMINES; ANTIVIRAL AGENTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MOLECULAR STRUCTURE; POLYCYCLIC COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884576955     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.06.006     Document Type: Article

References (56)

1. Alves Galvão M.G., Rocha Crispino Santos M.A., Alves da Cunha A.J. Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst. Rev. 2012, CD002745.
2. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A., Simpkins L.M., Taunk P., Huang Q., Han S.P., Abboa-Offei B., Cap M., Xin L., Tao L., Tozzo E., Welzel G.E., Egan D.M., Marcinkeviciene J., Chang S.Y., Biller S.A., Kirby M.S., Parker R.A., Hamann L.G. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48:5025-5037.
3. Balannik V., Wang J., Ohigashi Y., Jing X., Magavern E., Lamb R.A., DeGrado W.F., Pinto L.H. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 2009, 48:11872-11882.
4. Bao Y., Bolotov P., Dernovoy D., Kiryutin B., Zaslavsky L., Tatusova T., Ostell J., Lipman D. The influenza virus resource at the National Center for Biotechnology Information. J. Virol. 2008, 82:596-601.
5. Bright R.A., Medina M.J., Xu X., Pérez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366:1175-1181.
6. Bright R.A., Shay D.K., Shu B., Cox N.J., Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. Jama 2006, 295:891-894.
7. Cady S.D., Luo W., Hu F., Hong M. Structure and function of the influenza A M2 proton channel. Biochemistry 2009, 48:7356-7364.
8. Cady S.D., Schmidt-Rohr K., Wang J., Soto C.S., DeGrado W.F., Hong M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 2010, 463:689-692.
9. Cady S.D., Wang J., Wu Y., DeGrado W.F., Hong M. Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy. J. Am. Chem. Soc. 2011, 133:4274-4284.
10. RN1 mechanism. J. Org. Chem. 2001, 66:5366-5373.
11. Camps P., Duque M.D., Vázquez S., Naesens L., De Clercq E., Sureda F.S., López-Querol M., Camins A., Pallàs M., Prathalingam S.R., Kelly J.M., Romero V., Ivorra D., Cortés D. Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs. Bioorg. Med. Chem. 2008, 16:9925-9936.
12. Cross K.J., Burleigh L.M., Steinhauer D.A. Mechanisms of cell entry by influenza virus. Exp. Rev. Mol. Med. 2001, 3:1-18.
13. Cross K.J., Wharton S.A., Skehel J.J., Wiley D.C., Steinhauer D.A. Studies on influenza haemagglutinin fusion peptide mutants generated by reverse genetics. EMBO J. 2001, 20:4432-4442.
14. Daniels R.S., Downie J.C., Hay A.J., Knossow M., Skehel J.J., Wang M.L., Wiley D.C. Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell 1985, 40:431-439.
15. Duque M.D., Ma C., Torres E., Wang J., Naesens L., Juárez-Jiménez J., Camps P., Luque F.J., DeGrado W.F., Lamb R.A., Pinto L.H., Vázquez S. Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. J. Med. Chem. 2011, 54:2646-2657.
16. Fiore A.E., Fry A., Shay D., Gubareva L., Bresee J.S., Uyeki T.M. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2011, 60:1-24.
17. Gamblin S.J., Haire L.F., Russell R.J., Stevens D.J., Xiao B., Ha Y., Vasisht N., Steinhauer D.A., Daniels R.S., Elliot A., Wiley D.C., Skehel J.J. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 2004, 303:1838-1842.
18. Hay A.J., Wolstenholme A.J., Skehel J.J., Smith M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985, 4:3021-3024.
19. Hayden F.G., Minocha A., Spyker D.A., Hoffman H.E. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob. Agents Chemother. 1985, 28:216-221.
20. Hoffmann E., Stech J., Guan Y., Webster R.G., Pérez D.R. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol. 2001, 146:2275-2289.
21. Hong M., DeGrado W.F. Structural basis for proton conduction and inhibition by the influenza M2 protein. Protein Sci. 2012, 21:1620-1633.
22. Hu F., Luo W., Hong M. Mechanisms of proton conduction and gating in influenza M2 proton channels from solid-state NMR. Science 2010, 330:505-508.
23. Hubsher G., Haider M., Okun M.S. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 2012, 78:1096-1099.
24. Jefferson T., Demicheli V., Di Pietrantonj C., Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst. Rev. 2006, CD001169.
25. Korte T., Ludwig K., Booy F.P., Blumenthal R., Herrmann A. Conformational intermediates and fusion activity of influenza virus hemagglutinin. J Virol. 1999, 73:4567-4574.
26. Lamoureux G., Artavia G. Use of the adamantane structure in medicinal chemistry. Curr. Med. Chem. 2010, 17:2967-2978.
27. Lin Y.P., Wharton S.A., Martín J., Skehel J.J., Wiley D.C., Steinhauer D.A. Adaptation of egg-grown and transfectant influenza viruses for growth in mammalian cells: selection of hemagglutinin mutants with elevated pH of membrane fusion. Virology 1997, 233:402-410.
28. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 2006, 5:160-170.
29. Liu J., Obando D., Liao V., Lifa T., Codd R. The many faces of the adamantyl group in drug design. Eur. J. Med. Chem. 2011, 46:1949-1963.
30. Ma C., Soto C.S., Ohigashi Y., Taylor A., Bournas V., Glawe B., Udo M.K., DeGrado W.F., Lamb R.A., Pinto L.H. Identification of the pore-lining residues of the BM2 ion channel protein of influenza B virus. J. Biol. Chem. 2008, 283:15921-15931.
31. Naesens L., Vanderlinden E., Roth E., Jeko J., Andrei G., Snoeck R., Pannecouque C., Illyes E., Batta G., Herczegh P., Sztaricskai F. Anti-influenza virus activity and structure-activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains. Antiviral Res. 2009, 82:89-94.
32. +-ATPase activities relative to virus infection. J. Leukoc. Biol. 1998, 64:302-310.
33. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25:1605-1612.
34. Piérard G.E., Piérard-Franchimont C., Paquet P., Quatresooz P. Spotlight on adapalene. Expert Opin. Drug Metab. Toxicol. 2009, 5:1565-1575.
35. Pinto L.H., Lamb R.A. The M2 proton channels of influenza A and B viruses. J. Biol. Chem. 2006, 281:8997-9000.
36. Plotch S.J., O'Hara B., Morin J., Palant O., LaRocque J., Bloom J.D., Lang S.A., DiGrandi M.J., Bradley M., Nilakantan R., Gluzman Y. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J. Virol. 1999, 73:140-151.
37. Rachakonda P.S., Veit M., Korte T., Ludwig K., Böttcher C., Huang Q., Schmidt M.F., Herrmann A. The relevance of salt bridges for the stability of the influenza virus hemagglutinin. FASEB J. 2007, 21:995-1002.
38. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 1938, 27:493-497.
39. Rosenberg M.R., Casarotto M.G. Coexistence of two adamantane binding sites in the influenza A M2 ion channel. Proc. Natl. Acad. Sci. USA 2010, 107:13866-13871.
40. Rossman J.S., Lamb R.A. Influenza virus assembly and budding. Virology 2011, 411:229-236.
41. Scholtissek C., Quack G., Klenk H.D., Webster R.G. How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Res. 1998, 37:83-95.
42. Sharma M., Yi M., Dong H., Qin H., Peterson E., Busath D.D., Zhou H.-X., Cross T.A. Insight into the mechanisms of the influenza A proton channel from a structure in a lipid bilayer. Science 2010, 330:509-512.
43. Smith N.M., Bresee J.S., Shay D., Uyeki T.M., Cox N.J., Strikas R.A. Prevention and control of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2006, 55:1-42.
44. Stevens J., Corper A.L., Basler C.F., Taubenberger J.K., Palese P., Wilson I.A. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 2004, 303:1866-1870.
45. Stevens J., Blixt O., Tumpey T.M., Taubenberger J.K., Paulson J.C., Wilson I.A. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006, 312:404-410.
46. Stouffer A.L., Acharya R., Salom D., Levine A.S., Di Costanzo L., Soto C.S., Tereshko V., Nanda V., Stayrook S., DeGrado W.F. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008, 451:596-599.
47. Thoennes S., Li Z.N., Lee B.J., Langley W.A., Skehel J.J., Russell R.J., Steinhauer D.A. Analysis of residues near the fusion peptide in the influenza hemagglutinin structure for roles in triggering membrane fusion. Virology 2008, 370:403-414.
48. Torres E., Vanderlinden E., Fernández R., Miquet S., Font-Bardia M., Naesens L., Vázquez S. Synthesis and anti-influenza activity of 2,2-dialkylamantadines and related compounds. ACS Med. Chem. Lett. 2012, 3:1065-1069.
49. Vanderlinden E., Göktas F., Cesur Z., Froeyen M., Reed M.L., Russell C.J., Cesur N., Naesens L. Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J. Virol. 2010, 84:4277-4288.
50. Vanderlinden E., Vanstreels E., Boons E., ter Veer W., Huckriede A., Daelemans D., Van Lommel A., Röth E., Sztaricskai F., Herczegh P., Naesens L. Intracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin. J. Virol. 2012, 86:9416-9431.
51. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., Hughes T.E. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2003, 46:2774-2789.
52. Wang J., Ma C., Fiorin G., Carnevale V., Wang T., Hu F., Lamb R.A., Pinto L.H., Hong M., Klein M.L., DeGrado W.F. Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. J. Am. Chem. Soc. 2011, 133:12834-12841.
53. Wang J., Qui J.X., Soto C., DeGrado W.F. Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr. Opin. Struct. Biol. 2011, 21:68-80.
54. Wang J., Wu Y., Ma C., Fiorin G., Wang J., Pinto L.H., Lamb R.A., Klein M.L., DeGrado W.F. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc. Natl. Acad. Sci. USA 2013, 110:1315-1320.
55. Zhang W., Xu J., Liu F., Li C., Jie Y., Chen S., Li Z., Liu J., Chen L., Zhou G. Heterodimers of histidine and amantadine as inhibitors for wild type and mutant M2 channels of influenza A. Chin. J. Chem. 2010, 28:1417-1423.
56. Zhang W., Qi J., Shi Y., Li Q., Gao F., Sun Y., Lu X., Lu Q., Vavricka C.J., Liu D., Yan J., Gao G.F. Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell 2010, 1:459-467.